Country: Canada
Language: English
Source: Health Canada
METRONIDAZOLE
PFIZER CANADA ULC
J01XD01
METRONIDAZOLE
5MG
SOLUTION
METRONIDAZOLE 5MG
INTRAVENOUS
4X100ML
Prescription
MISCELLANEOUS ANTIPROTOZOALS
Active ingredient group (AIG) number: 0102572002; AHFS:
APPROVED
2004-03-05
_Pr_ _METRONIDAZOLE INJECTION USP – Product Monograph_ _ _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR METRONIDAZOLE INJECTION USP Metronidazole Solution, 5 mg / mL and I.V. infusion USP Antibacterial-Antiprotozoal ATC J01XD01 Pfizer Canada ULC 17300 Trans-Canada Highway Kirkland, Québec H9J 2M5 Date of Initial Authorization: MAR 10, 1987 Date of Revision: JUL 04, 2023 Submission Control Number: 272318 _ _ _Pr_ _METRONIDAZOLE INJECTION USP – Product Monograph_ _ _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 5 2 CONTRAINDICATIONS ................................................................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations ............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 5 4.4 Administration ......................................................................................................... 6 4.5 Missed Dose ............ Read the complete document